---
title: Role of Patents and RD in Pharma
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

The pharmaceutical industry, as exemplified by [[Insulin Market Dynamics and Innovations | Novo Nordisk]]'s century-long history, fundamentally relies on extensive research and development (R&D) and the strategic use of patents. This combination drives innovation, shapes market dynamics, and dictates profitability within the sector <a class="yt-timestamp" data-t="03:38:00">[03:38:00]</a>.

## Early Discoveries and Patent Limitations

In the early 20th century, breakthroughs like the discovery of insulin in 1921 highlighted the urgent need for mass production of life-saving treatments <a class="yt-timestamp" data-t="05:35:00">[05:35:00]</a>. However, early pharmaceutical science often operated in a context where making money from medical breakthroughs was perceived as unethical <a class="yt-timestamp" data-t="01:27:00">[01:27:00]</a>. For instance, in Denmark, it was initially not possible to patent drugs, leading to situations where discoveries could be freely replicated <a class="yt-timestamp" data-t="02:37:00">[02:37:00]</a>. This lack of patent protection directly influenced the early competitive landscape, such as the intense rivalry between Novo and Nordisk, both founded on insulin production, with Novo even offering its product at half price due to more efficient processes <a class="yt-timestamp" data-t="04:47:52">[04:47:52]</a>.

## The Rise of Modern Pharmaceutical R&D

The pharmaceutical industry's core function is R&D and production <a class="yt-timestamp" data-t="02:59:57">[02:59:57]</a>. The sheer cost and risk associated with bringing a new drug to market are staggering. On average, it costs $2.3 billion to develop and bring a drug to market <a class="yt-timestamp" data-t="02:48:47">[02:48:47]</a>, with the majority of this expense ($2.5 billion today, compared to $40 million in 1953, inflation-adjusted) occurring during the clinical trial phases <a class="yt-timestamp" data-t="03:11:03">[03:11:03]</a>.

### Clinical Trial Phases:
*   **Phase 1:** Focuses on safety and dosage, often in healthy volunteers. Represents 9% of total R&D cost <a class="yt-timestamp" data-t="01:56:16">[01:56:16]</a>.
*   **Phase 2:** Establishes preliminary evidence of efficacy in patients. Accounts for 12% of R&D cost <a class="yt-timestamp" data-t="01:56:20">[01:56:20]</a>.
*   **Phase 3:** Confirms efficacy in a larger patient sample and collects robust safety data. This is the most expensive phase, consuming 29% of R&D spending <a class="yt-timestamp" data-t="01:56:24">[01:56:24]</a>.

The probability of a drug making it from preclinical study to market is very low, with only about 8% graduating from Phase 3 trials <a class="yt-timestamp" data-t="01:57:48">[01:57:48]</a>. This high failure rate means that successful drugs must generate substantial profits to offset the many failures and immense upfront investment <a class="yt-timestamp" data-t="03:11:53">[03:11:53]</a>. Most drugs, even if approved, do not earn back their R&D costs <a class="yt-timestamp" data-t="03:13:02">[03:13:02]</a>. The top 10% of pharmaceuticals generate 50% of the industry's profits <a class="yt-timestamp" data-t="03:12:32">[03:12:32]</a>.

## The Impact of Genetic Engineering

The landscape of R&D was revolutionized by the advent of [[Qualcomms technological innovations and patents | genetic engineering]] and [[Role of Electronic Design Automation EDA in Chip Design | recombinant DNA]] technology in the 1980s. [[Role of Electronic Design Automation EDA in Chip Design | Genentech]], in partnership with Eli Lilly, pioneered the first genetically engineered drug: human insulin <a class="yt-timestamp" data-t="01:14:53">[01:14:53]</a>. This breakthrough not only eliminated reliance on animal pancreases for insulin production (which required 1 million animals annually for just 30,000 patients in 1980) <a class="yt-timestamp" data-t="02:06:00">[02:06:00]</a>, but also marked the beginning of modern biotechnology's commercialization <a class="yt-timestamp" data-t="01:19:10">[01:19:10]</a>.

This era led to increased R&D costs and a greater emphasis on scale in pharmaceutical operations <a class="yt-timestamp" data-t="02:18:20">[02:18:20]</a>. Companies needed significant capital for production, trials, and market negotiation <a class="yt-timestamp" data-t="02:18:20">[02:18:20]</a>.

## Patents as a Core Power

Patents are a primary source of competitive advantage (a "cornered resource") in the pharmaceutical industry <a class="yt-timestamp" data-t="02:44:57">[02:44:57]</a>. When a company holds a patent on a drug, it typically enjoys high profitability. However, these patents are "fairly narrow" <a class="yt-timestamp" data-t="00:50:10">[00:50:10]</a>, specifically covering a molecule, allowing competitors to develop similar molecules or processes that achieve the same biological effect without infringing the patent <a class="yt-timestamp" data-t="00:50:37">[00:50:37]</a>.

Beyond molecules, patents also cover delivery mechanisms, like the insulin pen invented by Novo <a class="yt-timestamp" data-t="00:45:02">[00:45:02]</a>. Continual innovation in both drug formulation and delivery systems provides ongoing defensibility and allows companies to maintain market leadership, even after initial patents expire <a class="yt-timestamp" data-t="02:47:25">[02:47:25]</a>.

## The GLP-1 Breakthrough

The development of GLP-1 (glucagon-like peptide 1) drugs like semaglutide ([[Insulin Market Dynamics and Innovations | Ozempic]] and [[Insulin Market Dynamics and Innovations | Wegovy]]) by [[Insulin Market Dynamics and Innovations | Novo Nordisk]] exemplifies the culmination of decades of focused R&D <a class="yt-timestamp" data-t="02:15:02">[02:15:02]</a>. Initial research into GLP-1 began in the early 1990s <a class="yt-timestamp" data-t="02:56:00">[02:56:00]</a>, facing skepticism and industry abandonment due to the short half-life of natural GLP-1 <a class="yt-timestamp" data-t="01:47:19">[01:47:19]</a>. However, persistent internal research by scientists like Lotte Bjerre Knudsen led to the discovery of Liraglutide (Victoza, Saxenda), which had a 13-hour half-life <a class="yt-timestamp" data-t="01:49:04">[01:49:04]</a>, and later Semaglutide, with a half-life measured in days, enabling once-weekly injections <a class="yt-timestamp" data-t="02:15:34">[02:15:34]</a>.

The ability to chemically modify existing molecules or discover naturally occurring analogs (like the Gila monster venom-derived Exenatide, which became Eli Lilly's Byetta) demonstrates the varied paths to pharmaceutical innovation <a class="yt-timestamp" data-t="01:51:59">[01:51:59]</a>. [[Insulin Market Dynamics and Innovations | Novo Nordisk]] holds the patent for Semaglutide until 2032 <a class="yt-timestamp" data-t="02:45:48">[02:45:48]</a>.

## Market Dynamics and the Future

The R&D-heavy nature of the pharma industry results in high gross margins for successful products (e.g., [[Insulin Market Dynamics and Innovations | Novo Nordisk]] at 84%, Eli Lilly at 80%) <a class="yt-timestamp" data-t="02:28:28">[02:28:28]</a>. This profitability is necessary to cover the extensive R&D costs and the high failure rate of experimental drugs <a class="yt-timestamp" data-t="03:23:59">[03:23:59]</a>. Despite perceptions of "over-earning," the industry's return on invested capital (ROIC) is often on par with other capital-intensive industries when considering all R&D expenses and failures <a class="yt-timestamp" data-t="03:24:41">[03:24:41]</a>.

However, the industry faces challenges, including the rise of biosimilars (generic versions of biologic drugs derived from living cells) <a class="yt-timestamp" data-t="02:42:20">[02:42:20]</a>, which can significantly erode profits after patent expiration. The success of GLP-1 drugs highlights a shift back towards large-population, mass-market drugs, which historically have been less common than specialty "orphan" drugs due to regulatory hurdles and the "better than the Beatles" problem (new drugs needing to significantly outperform existing treatments) <a class="yt-timestamp" data-t="03:07:29">[03:07:29]</a>.

The long-term focus and sustained R&D investment, particularly by companies like [[Insulin Market Dynamics and Innovations | Novo Nordisk]] with unique foundation ownership structures that prioritize long-term mission over short-term stock performance <a class="yt-timestamp" data-t="03:05:58">[03:05:58]</a>, appear to be key factors in achieving breakthroughs that transform the market.